Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + oxaliplatin + S-1 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Camrelizumab + oxaliplatin + S-1 + trastuzumab is a combination chemo-immunotherapy regimen currently being evaluated in Phase II clinical trials for the neoadjuvant treatment of HER2-positive, resectable, locally advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. This multi-modal regimen combines camrelizumab, a PD-1 checkpoint inhibitor, with trastuzumab, a monoclonal antibody targeting the HER2 receptor, and the SOX chemotherapy backbone (consisting of oxaliplatin and the oral fluoropyrimidine S-1). The combination is designed to improve pathological complete response (pCR) rates by simultaneously inhibiting immune evasion via the PD-1/PD-L1 pathway, blocking HER2-mediated oncogenic signaling, and inducing cytotoxic cell death through DNA damage and inhibition of thymidylate synthase.
- Other names
- Camrelizumab + SOX + TrastuzumabCamrelizumab + Oxaliplatin + S-1 + Trastuzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on camrelizumab + oxaliplatin + S-1 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + oxaliplatin + S-1 + trastuzumab.